247 related articles for article (PubMed ID: 19519779)
21. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis.
Zhang L; Wang L; Dong D; Wang Z; Ji W; Yu M; Zhang F; Niu R; Zhou Y
Cell Prolif; 2019 Jan; 52(1):e12527. PubMed ID: 30334298
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of NK1R attenuates LPS-induced microglial inflammation and consequent death of PC12 cells.
Jiang W; Wang X; Wang W; Hua F; Zhang Z; Zhang Z; Xiang J; Yang X
Brain Res Bull; 2020 Sep; 162():115-124. PubMed ID: 32540418
[TBL] [Abstract][Full Text] [Related]
23. Expression of different neurokinin-1 receptor (NK1R) isoforms in glioblastoma multiforme: potential implications for targeted therapy.
Cordier D; Gerber A; Kluba C; Bauman A; Hutter G; Mindt TL; Mariani L
Cancer Biother Radiopharm; 2014 Jun; 29(5):221-6. PubMed ID: 24552486
[TBL] [Abstract][Full Text] [Related]
24. Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors.
Palma C; Nardelli F; Manzini S; Maggi CA
Br J Cancer; 1999 Jan; 79(2):236-43. PubMed ID: 9888463
[TBL] [Abstract][Full Text] [Related]
25. Tachykinin Receptor-Selectivity of the Potential Glioblastoma-Targeted Therapy, DOTA-[Thi
Suthiram J; Pieters A; Mohamed Moosa Z; Zeevaart JR; Sathekge MM; Ebenhan T; Anderson RC; Newton CL
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768456
[TBL] [Abstract][Full Text] [Related]
26. Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity.
Janelsins BM; Mathers AR; Tkacheva OA; Erdos G; Shufesky WJ; Morelli AE; Larregina AT
Blood; 2009 Mar; 113(13):3017-26. PubMed ID: 18987361
[TBL] [Abstract][Full Text] [Related]
27. Substance P receptor in U373 MG human astrocytoma cells activates mitogen-activated protein kinases ERK1/2 through Src.
Yamaguchi K; Kugimiya T; Miyazaki T
Brain Tumor Pathol; 2005; 22(1):1-8. PubMed ID: 18095097
[TBL] [Abstract][Full Text] [Related]
28. Anti‑inflammatory actions of gabapentin and pregabalin on the substance P‑induced mitogen‑activated protein kinase activation in U373 MG human glioblastoma astrocytoma cells.
Yamaguchi K; Kumakura S; Someya A; Iseki M; Inada E; Nagaoka I
Mol Med Rep; 2017 Nov; 16(5):6109-6115. PubMed ID: 28849160
[TBL] [Abstract][Full Text] [Related]
29. Substance P enhances the local activation of NK
Jeong YM; Cheng XW; Lee KH; Lee S; Cho H; Kim W
BMC Mol Cell Biol; 2020 Jun; 21(1):41. PubMed ID: 32517655
[TBL] [Abstract][Full Text] [Related]
30. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
Nizam E; Köksoy S; Erin N
Cancer Immunol Immunother; 2020 Aug; 69(8):1639-1650. PubMed ID: 32322911
[TBL] [Abstract][Full Text] [Related]
31. Cellular and behavioral effects of lipopolysaccharide treatment are dependent upon neurokinin-1 receptor activation.
Fulenwider HD; Smith BM; Nichenko AS; Carpenter JM; Nennig SE; Cheng K; Rice KC; Schank JR
J Neuroinflammation; 2018 Feb; 15(1):60. PubMed ID: 29486768
[TBL] [Abstract][Full Text] [Related]
32. The effect of CP96,345 on the expression of tachykinins and neurokinin receptors in acute pancreatitis.
Lau HY; Bhatia M
J Pathol; 2006 Feb; 208(3):364-71. PubMed ID: 16369913
[TBL] [Abstract][Full Text] [Related]
33. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
34. The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification.
Rezaei S; Assaran Darban R; Javid H; Hashemy SI
Biomed Res Int; 2022; 2022():8540403. PubMed ID: 35281606
[TBL] [Abstract][Full Text] [Related]
35. Role of PKC-delta on substance P-induced chemokine synthesis in pancreatic acinar cells.
Ramnath RD; Sun J; Adhikari S; Zhi L; Bhatia M
Am J Physiol Cell Physiol; 2008 Mar; 294(3):C683-92. PubMed ID: 18160487
[TBL] [Abstract][Full Text] [Related]
36. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I; Lieb K
CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
[TBL] [Abstract][Full Text] [Related]
37. Regulated norepinephrine transporter interaction with the neurokinin-1 receptor establishes transporter subcellular localization.
Arapulisamy O; Mannangatti P; Jayanthi LD
J Biol Chem; 2013 Oct; 288(40):28599-610. PubMed ID: 23979140
[TBL] [Abstract][Full Text] [Related]
38. Functional consequences of alteration of N-linked glycosylation sites on the neurokinin 1 receptor.
Tansky MF; Pothoulakis C; Leeman SE
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10691-6. PubMed ID: 17563389
[TBL] [Abstract][Full Text] [Related]
39. Induction of the neurokinin 1 receptor by TNFα in endometriotic tissue provides the potential for neurogenic control over endometriotic lesion growth.
McKinnon BD; Evers J; Bersinger NA; Mueller MD
J Clin Endocrinol Metab; 2013 Jun; 98(6):2469-77. PubMed ID: 23553861
[TBL] [Abstract][Full Text] [Related]
40. Blockade of neurokinin-1 receptors in the ventral respiratory column does not affect breathing but alters neurochemical release.
Muere C; Neumueller S; Olesiak S; Miller J; Hodges MR; Pan L; Forster HV
J Appl Physiol (1985); 2015 Mar; 118(6):732-41. PubMed ID: 25635003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
